FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4286296227> ?p ?o ?g. }

• W4286296227 endingPage "e15066" @default.
• W4286296227 startingPage "e15066" @default.
• W4286296227 abstract "e15066 Background: Clinicians generally deal with malignant tumors in progression phase only, but there is a reverse complimentary process, namely permanent spontaneous regression of tumors, a well-known phenomenon occurring across human populations at 22%-46% rate (Scandinavian and Wisconsin Screening Registries: 0.33 million and 2.95 million populace respectively; Lancet Oncol.12: 1118-24, 2011; J.Nat.Cancer.Inst.36: 37-47, 2006). Probing such a phenomenon can illuminate how one can induce a permanent regression process on human tumors therapeutically. Here we develop a systems biology approach for this process, that we validate by experimental findings. Methods: Mathematical System Biology Formulation: For permanent tumor regression, we develop a coupled differential equations-based cell kinetic analysis, keeping normal tissue protected. Thereby, we mathematically model the temporal variation of the level of three essential tumor-lysis components: DNA replication-blockade, Antitumor Lymphocyte, Cytokine interleukin-2. Experimental Investigation: We investigate the temporal process of spontaneous tumor regression of melanoma (in Liebechov pigs) and analyze the microarray signal using IPA platform Gene expression signature: Using IPA analysis, we find the signaling pathways associated with the permanent tumor regression. Results: Mathematical System Biology Formulation: We find the temporal behavior of tumor-lysis components are: (1) DNA replication-blockade activation: Unimodal inverted U function (2) Antitumor Lymphocyte activation: Bimodal M function; (3) Interleukin-2 activation as Stationary step function. Experimental findings: Our microarray analysis gives temporal pattern of gene-expression levels corresponding to above three components: G2/M DNA damage checkpoint regulation (genes CCNB1, CDC2), Chemokine signaling activation - Interleukin 2 ( GRB2, PIK3CG), T Lymphocyte Receptor Signaling (CCR5, PRF1). These three temporal components respectively show Unimodal, Bimodal, and Stationary activation. Validation: We show that the three mathematically-derived temporal activation functions are well corroborated by corresponding experimental temporal pathway activation data (Smirnov-Kolmogorov statistical test satisfied; α = 5%). Conclusions: A novel tri-phasic activation of three antitumor signaling pathways (DNA blockade, Interleukin 2, Cytotoxic T cell) can permanently regress melanoma tumor in the experimental setting if the pathways are activated at different time points and not simultaneously; These temporally orchestrated patterns are much different from conventional chemotherapy/ immunotherapy protocols where the temporal activations are simultaneous and empirically chosen. Optimal temporal profiling of administration of antitumor agents is thus crucial from a therapeutic standpoint." @default.
• W4286296227 created "2022-07-21" @default.
• W4286296227 creator A5015646157 @default.
• W4286296227 creator A5037549781 @default.
• W4286296227 creator A5074132825 @default.
• W4286296227 creator A5088762394 @default.
• W4286296227 date "2022-06-01" @default.
• W4286296227 modified "2023-10-16" @default.
• W4286296227 title "Systems biology basis of permanent tumor regression with normal tissue protection: Experimentally validated signaling pathway framework." @default.
• W4286296227 doi "https://doi.org/10.1200/jco.2022.40.16_suppl.e15066" @default.
• W4286296227 hasPublicationYear "2022" @default.
• W4286296227 type Work @default.
• W4286296227 citedByCount "0" @default.
• W4286296227 crossrefType "journal-article" @default.
• W4286296227 hasAuthorship W4286296227A5015646157 @default.
• W4286296227 hasAuthorship W4286296227A5037549781 @default.
• W4286296227 hasAuthorship W4286296227A5074132825 @default.
• W4286296227 hasAuthorship W4286296227A5088762394 @default.
• W4286296227 hasConcept C105795698 @default.
• W4286296227 hasConcept C121608353 @default.
• W4286296227 hasConcept C33923547 @default.
• W4286296227 hasConcept C502942594 @default.
• W4286296227 hasConcept C54355233 @default.
• W4286296227 hasConcept C70721500 @default.
• W4286296227 hasConcept C83546350 @default.
• W4286296227 hasConcept C86803240 @default.
• W4286296227 hasConceptScore W4286296227C105795698 @default.
• W4286296227 hasConceptScore W4286296227C121608353 @default.
• W4286296227 hasConceptScore W4286296227C33923547 @default.
• W4286296227 hasConceptScore W4286296227C502942594 @default.
• W4286296227 hasConceptScore W4286296227C54355233 @default.
• W4286296227 hasConceptScore W4286296227C70721500 @default.
• W4286296227 hasConceptScore W4286296227C83546350 @default.
• W4286296227 hasConceptScore W4286296227C86803240 @default.
• W4286296227 hasIssue "16_suppl" @default.
• W4286296227 hasLocation W42862962271 @default.
• W4286296227 hasOpenAccess W4286296227 @default.
• W4286296227 hasPrimaryLocation W42862962271 @default.
• W4286296227 hasRelatedWork W2042520059 @default.
• W4286296227 hasRelatedWork W2109763600 @default.
• W4286296227 hasRelatedWork W2339808165 @default.
• W4286296227 hasRelatedWork W2344637265 @default.
• W4286296227 hasRelatedWork W2467622083 @default.
• W4286296227 hasRelatedWork W2771066073 @default.
• W4286296227 hasRelatedWork W2792929645 @default.
• W4286296227 hasRelatedWork W2984941165 @default.
• W4286296227 hasRelatedWork W826282941 @default.
• W4286296227 hasRelatedWork W2760557785 @default.
• W4286296227 hasVolume "40" @default.
• W4286296227 isParatext "false" @default.
• W4286296227 isRetracted "false" @default.
• W4286296227 workType "article" @default.